康寧傑瑞製藥-B(09966.HK)：於2023年ASCO年會上呈列KN026聯合KN046的研究進展

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

康寧傑瑞製藥-B(09966.HK)：於2023年ASCO年會上呈列KN026聯合KN046的研究進展

格隆匯 06-06 06:42

格隆匯6月6日丨康寧傑瑞製藥-B(09966.HK)發佈公吿，已於2023年ASCO年會上呈列KN026聯合KN046用於治療局部晚期不可切除或轉移性HER2陽性實體瘤(BC或GC/GEJ除外)II期臨牀試驗的最新研究結果(摘要編號：3621，壁報編號：321)，亦已於公司網站 http://www.alphamabonc.com相應公佈。

康寧傑瑞製藥-B(09966.HK)

Relevant Stocks

康寧傑瑞製藥-B(09966.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

康寧傑瑞製藥-B(09966.HK)：於2023年ASCO年會上呈列KN026聯合KN046的研究進展

Services

About Us

Agreement Statement